PharmGen Science Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

PharmGen Science, Inc.'s (KRX:004720) Share Price Could Signal Some Risk

Aug 12

PharmGen Science's (KRX:004720) Shareholders Have More To Worry About Than Only Soft Earnings

Mar 27

Is Wooridul Pharmaceutical (KRX:004720) A Risky Investment?

Mar 21

Investors Who Bought Wooridul Pharmaceutical (KRX:004720) Shares Five Years Ago Are Now Up 55%

Jan 19

Does The Market Have A Low Tolerance For Wooridul Pharmaceutical Limited's (KRX:004720) Mixed Fundamentals?

Dec 21

Are Wooridul Pharmaceutical's (KRX:004720) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 25

CEO

PharmGen Science has no CEO, or we have no data on them.

PharmGen Science Management

Management criteria checks 0/4

Key information

Recent management updates

Wooridul Pharmaceutical Limited, Annual General Meeting, Mar 25, 2021

Recent updates

PharmGen Science, Inc.'s (KRX:004720) Share Price Could Signal Some Risk

PharmGen Science's (KRX:004720) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings released: EPS: ₩352 (vs ₩4,498 in FY 2022)

New minor risk - Shareholder dilution

Investor sentiment deteriorates as stock falls 18%

Full year 2022 earnings released: EPS: ₩4,498 (vs ₩2,206 in FY 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

PharmGen Science Inc. announced that it has received KRW 30 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) Limited

Investor sentiment deteriorated over the past week

PharmGen Science Inc. announced that it expects to receive KRW 30 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) Limited

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Is Wooridul Pharmaceutical (KRX:004720) A Risky Investment?

Full year 2020 earnings released: EPS ₩675 (vs ₩26.00 in FY 2019)

Wooridul Pharmaceutical Limited, Annual General Meeting, Mar 25, 2021

New 90-day low: ₩9,180

New 90-day low: ₩9,340

Investors Who Bought Wooridul Pharmaceutical (KRX:004720) Shares Five Years Ago Are Now Up 55%

New 90-day low: ₩10,350

Investor sentiment deteriorated over the past week

New 90-day low: ₩11,800

Does The Market Have A Low Tolerance For Wooridul Pharmaceutical Limited's (KRX:004720) Mixed Fundamentals?

New 90-day low: ₩11,900

Are Wooridul Pharmaceutical's (KRX:004720) Statutory Earnings A Good Reflection Of Its Earnings Potential?

New 90-day low: ₩12,250

Wooridul Pharmaceutical Limited announced that it expects to receive KRW 20 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) Limited

New 90-day high - ₩20,300

New 90-day high - ₩7,380

CEO